U.S. Court of Appeals rules that the PTAB applied the wrong legal standard for conception in the CRISPR-Cas9 interference dispute with the Broad Institute.  Decision sent back to the PTAB for reconsideration under the correct legal standard for assessing the inventor of CRISPR-Cas9 gene editing in eukaryotic cells.    Dublin, Ireland, May 13, 2025: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, today announced the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has been ordered to reconsider its 2022 interference decision that scientists at the Broad Institute in Boston invented CRISPR-Cas9 gene editing in eukaryotic cells.